# Phase 0 Acceptance Report

| Field | Value |
|---|---|
| Phase | 0 — Product charter and compliance boundary |
| Report version | 1.0.0 |
| Candidate date | 2026-09-15 |
| Accountable owner | Shyamal Patel |
| Status | Approved |
| Intended immutable tag | `phase-0-v1.0.0` |

## Exit-gate assessment

| Gate | Result | Evidence |
|---|---|---|
| Every V1 requirement has stable ID, owner, source, verification, and acceptance criterion. | Candidate pass | `requirements-traceability.md` |
| Every firm rule has source evidence and effective date. | Candidate pass with fail-closed qualifications | `prop-firm-rule-packs.md` records the source and either a stated effective point or “not established”; absent dates are deployment-blocking, never assumed. |
| Every ambiguous/contradictory rule is deployment-blocking. | Candidate pass | All current rule rows remain `DEPLOYMENT_BLOCKING`; explicit evidence-to-unblock list is present. |
| Charter, requirements, threat model, risk register, definitions, initial rule packs, and acceptance matrix exist. | Candidate pass | Phase 0 package index |
| Required accountable roles and separation-of-duties exception are defined. | Candidate pass | `product-charter.md` approval matrix |
| Reference workstation and reproducible measurement method are defined. | Candidate pass | `reference-workstation.md` |
| Retention, backup/restore, incident, and change policies are defined. | Candidate pass | `operations-policies.md` |
| Demonstration artifact and known limitations exist. | Candidate pass | `demonstration.md` |

## Universal definition-of-done assessment

| Item | Result | Rationale/evidence |
|---|---|---|
| Phase requirements implemented without unfinished-work markers | Candidate pass | All Phase 0 deliverables exist; unresolved external facts are explicit blockers, not placeholders. |
| Unit/integration/replay/acceptance tests | Acceptance validation applicable | Phase 0 is documentation-only; consolidated document/evidence validation is recorded below. |
| Coverage and mutation thresholds | Not applicable | No production code or safety branch was authorized in Phase 0. |
| Determinism/reproducibility tests | Not applicable to code | Benchmark method and future provenance requirements are defined. |
| Performance benchmarks | Not applicable | Workstation/method are defined; corresponding implementations and fixtures belong to later phases. |
| Security, secret, dependency, vulnerability, and license scans | Secret/source-content inspection applicable | There are no dependencies or build artifacts; public-repository evidence policy is defined. |
| Database migration tests | Not applicable | No database or migration exists or is authorized. |
| User-facing failure messages | Not applicable | No UI or API exists. |
| Documentation, runbooks, threat model, and risk register current | Candidate pass for applicable Phase 0 artifacts | Threat, risk, incident, backup, restore, retention, and change policies are included. Operational runbooks belong to later phases. |
| No unresolved P0/P1 defect | Candidate pass | No operational system exists and no P0/P1 defect was identified in the documentation package. Firm evidence gaps are tracked as deployment blockers/risks. |
| Immutable accepted tag | Pending | Created only after explicit owner sign-off and committed acceptance record. |
| Strategy import/backtest/version/deployment universal gates | Not applicable | Strategy SDK, import validation, backtester, and deployment manager are later phases and were not implemented early. |

## Consolidated validation evidence

Status: **PASS**. See `validation-report.md` for the recorded single end-of-phase validation run. It verified required artifacts, documentation-only scope, unique and complete traceability IDs, source-manifest metadata and local SHA-256 values, deployment-blocking treatment, risk/threat registers, secret/unfinished-work scans, and Git whitespace integrity.

## Open risks and limitations

The risks in `security-and-risk.md` remain open according to their lifecycle. In particular, `RSK-004`, `RSK-005`, `RSK-006`, and `RSK-015` prevent firm-dependent deployment. Accepting Phase 0 approves the baseline and its fail-closed treatment; it does not accept these risks for trading.

## Owner sign-off

**Approved by:** Shyamal Patel  
**Approval date:** 2026-09-15  
**Approval evidence:** Owner directive in the QuantBench task: “get on with phase 1.”  
**Approval scope:** Phase 0 documentation baseline only.

This approval accepts the documented fail-closed treatment of evidence gaps. It does not mark preliminary firm rules safe, accept deployment-blocking risks for trading, or grant operational trading authority.

